Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant.

Johan CourjonVera PortilloSabine YerlyPauline VetterManuel SchiblerMaria MappouraSarah MorinFederica GiannottiAnne-Claire MamezChristian van DeldenLaurent KaiserYves ChalandonStavroula Masouridi-LevratDionysios Neofytos

Published in: Open forum infectious diseases (2023)

Among 292 recipients of allogeneic hematopoietic cell transplant (2018-2022), 64 (21.9%) tested positive for anti-hepatitis E virus (HEV) immunoglobulin G. Among 208 recipients tested by plasma/serum HEV polymerase chain reaction (2012-2022), 3 (1.4%) primary HEV infections were diagnosed; in 1 patient, plasma HEV polymerase chain reaction relapsed positive for 100 days. HEV infection remains rare albeit associated with persistent viral replication.

Keyphrases

bone marrow
stem cell transplantation
single cell
kidney transplantation
cell therapy
acute myeloid leukemia
sars cov
acute lymphoblastic leukemia
hematopoietic stem cell
risk factors
diffuse large b cell lymphoma
mesenchymal stem cells
case report
stem cells